Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06446206 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Adebrelimab Plus Chemotherapy, Bevacizumab and Fluzoparib in Platinum-Sensitive Relapsed Ovarian Cancer

Name: Adebrelimab Plus Chemotherapy, Bevacizumab and Fluzoparib in Platinum-Sensitive Relapsed Ovarian Cancer — clinical trial record (NCT06446206)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusNot Yet Recruiting

PhasePhase 2

SponsorThe First Hospital of Jilin University

Started2024-06

View on ClinicalTrials.gov ↗

Record status

This record was last updated June 6, 2024 (before its estimated June 2026 completion). Its status may not reflect the trial's current state.

The First Hospital of Jilin University

86 trials monitored

See 2 trials at risk

Ovarian Cancer

1,239 trials monitored

See 74 trials at risk

The investigators explore the efficacy and safety of adebrelimab (PD-L1 inhibitor) plus chemotherapy and bevacizumab induction therapy followed by maintenance therapy with adebrelimab plus fluzoparib (PARP inhibitor)and bevacizumab in platinum-sensitive relapsed ovarian cancer.

Trial Details

NCT Number	NCT06446206
Lead Sponsor	The First Hospital of Jilin University
Conditions	Platinum-sensitive Relapsed Ovarian Cancer
Enrollment	22 participants
Start Date	2024-06
Primary Completion	2026-06 (estimated)
Study Completion	2028-06 (estimated)
Updated on ClinicalTrials.gov	2024-06-06